샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514157

세계의 RNA 간섭(RNAi) 시장

RNA Interference (RNAi)
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 178 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 RNA 간섭(RNAi) 시장은 2030년까지 2,067억 달러에 달할 전망

2023년에 994억 달러로 평가된 세계의 RNA 간섭(RNAi) 시장은 분석 기간 2023년부터 2030년까지 CAGR 11.0%로 성장할 전망이며, 2030년에는 2,067억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 창약 개발 애플리케이션은 CAGR 16.4%로 성장을 지속하고, 분석 기간 종료 시에는 1,181억 달러에 달할 것으로 예측됩니다. 치료제 응용 분야의 성장률은 분석 기간 동안 CAGR 5.7%로 추정됩니다.

미국 시장은 256억 달러로 추정, 중국은 CAGR 17.3%로 성장 예측

미국의 RNA 간섭(RNAi) 시장은 2023년 256억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 595억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 17.3%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.2%와 8.4%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 6.4%로 성장할 것으로 예측됩니다.

세계의 RNA 간섭(RNAi)시장-동향 및 촉진요인 정리

RNA 간섭(RNAi)은 RNA 분자가 유전자 발현을 저해하는 중요한 생물학적 과정이며, 표적이 되는 메신저 RNA(mRNA) 분자를 중화하여 유전자를 침묵시키는 역할로부터 발견된 메커니즘입니다. 유전자의 코딩, 해독, 제어, 발현에 필수적인 RNA는 각각 약 22개 뉴클레오티드 길이의 저분자 간섭 RNA(siRNA)와 마이크로RNA(miRNA)라는 두 유형의 저분자 RNA 분자에 의해 RNAi를 촉진합니다. siRNA는 특정 mRNA를 특이적으로 표적으로 하고 침묵시키고 단백질의 생산을 차단하도록 설계되었으며, 이중 가닥 RNA로부터 가공되고 절단되어 세포질로 수송됩니다. 반대로 miRNA는 헤어핀 구조로 접힌 단일 가닥 RNA로 만들어져 널리 단백질 합성을 조절합니다. 앤드류 파이어와 크레이그 멜로에게 2006년 노벨상을 가져온 이 발견은 RNAi가 유전체 기생충에 대한 자연적인 방어이며 단백질 합성에서 중요한 조절인자임을 분명히 했습니다.

RNAi 메커니즘은 siRNA와 miRNA가 RNA 유도 침묵 복합체(RISC)를 표적 mRNA로 유도하고 mRNA의 번역을 억제하고 분해를 신호하는 복잡한 경로에서 작동합니다. 이 과정은 mRNA가 단백질 합성에 필요한 수명을 초과하지 않도록 매우 중요합니다. RNAi의 치료 의의는 크고 분자 생물학에서 유전자 발현을 미세 조정하는 정밀한 도구를 제공하여 유전자 기능의 연구나 창약 표적의 검증에 도움이 될 수 있습니다. 이 방법은 유전체을 변화시키지 않고 단백질의 발현을 감소시키고 기능을 조사하는 '넉다운' 실험에서 특히 유용합니다. 특정 유전자를 선택적으로 저해하는 RNAi의 능력은 질병을 관리하기 위한 강력한 후보가 되어, 기능부전에 빠진 단백질을 표적으로 함으로써, 종래는 기존의 치료법으로는 어려웠던 병태에 새로운 치료 수단을 제공합니다.

RNAi 기술은 지질 나노입자를 이용한 RNAi 전달 기구의 개량, 안정된 RNAi 화합물의 개발, 유전자 타겟팅의 정밀도 향상 등의 진보에 추진되어 의료와 농업의 두 분야에서 성장의 원동력이 되고 있습니다. CRISPR과 같은 다른 유전체 도구와의 통합은 유전체 연구에서 유용성을 향상시킵니다. 게다가, RNAi의 특이성에 의해 개별 유전자 프로파일에 맞춘 치료가 가능해지는 맞춤형 의료에 대한 수요 증가는 커스텀 치료 전략에 있어서의 RNAi의 가능성을 부각시키고 있습니다. 농업 분야에서는 수확량 증가, 해충 저항성, 영양 프로파일의 개선을 수반하는 작물의 개발에 있어서의 RNAi의 응용이 지속 가능한 실천에의 공헌을 실증하고 있습니다. RNAi 기반 치료제에 대한 규제 당국의 승인과 관민 쌍방으로부터의 다액의 자금 제공에 의해 RNAi 기술의 채용과 개발이 가속되고 있어, 유전자 치료, 의약품 개발, 환경 지속가능성에 있어서의 큰 진보가 기대되고 있다 있습니다.

조사 대상 기업 예(주목의 12사)

  • Alnylam Pharmaceuticals, Inc.
  • Benitec BioPharma
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Qiagen, Inc.
  • Quark Pharmaceuticals, Inc.
  • Silence Therapeutics PLC

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global RNA Interference (RNAi) Market to Reach US$206.7 Billion by 2030

The global market for RNA Interference (RNAi) estimated at US$99.4 Billion in the year 2023, is expected to reach US$206.7 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2023-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 16.4% CAGR and reach US$118.1 Billion by the end of the analysis period. Growth in the Therapeutics Application segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.6 Billion While China is Forecast to Grow at 17.3% CAGR

The RNA Interference (RNAi) market in the U.S. is estimated at US$25.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$59.5 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global RNA Interference (RNAi) Market - Key Trends and Drivers Summarized

RNA interference (RNAi) is a vital biological process where RNA molecules inhibit gene expression, a mechanism discovered due to its role in silencing genes by neutralizing targeted messenger RNA (mRNA) molecules. RNA, essential in the coding, decoding, regulation, and expression of genes, facilitates RNAi through two types of small RNA molecules: small interfering RNA (siRNA) and microRNA (miRNA), each about 22 nucleotides long. SiRNAs are engineered to specifically target and silence particular mRNAs, preventing protein production, and are processed from double-stranded RNA, which is cleaved and transported into the cytoplasm. Conversely, miRNAs, originating from single-stranded RNA that folds into hairpin structures, broadly regulate protein synthesis. This discovery, which brought Andrew Fire and Craig Mello the Nobel Prize in 2006, underscored RNAi as a natural defense against genomic parasites and a crucial regulator in protein synthesis.

The RNAi mechanism operates through a complex pathway where siRNAs and miRNAs guide the RNA-induced silencing complex (RISC) to target mRNAs, blocking their translation and signaling their degradation. This process is pivotal for ensuring that mRNAs do not exceed their necessary lifespan in protein synthesis. The therapeutic implications of RNAi are significant, providing a precise tool in molecular biology to fine-tune gene expression for studying gene functions and validating drug targets. This method is particularly valuable in "knockdown" experiments, where protein expression is reduced to investigate function without altering the genome. RNAi's ability to selectively inhibit specific genes makes it a powerful candidate for managing diseases, offering new treatment avenues for conditions traditionally challenging with existing therapies by targeting malfunctioning proteins.

RNAi technology is a growth driver in both medical and agricultural fields, propelled by advancements such as improved RNAi delivery mechanisms using lipid nanoparticles, development of stable RNAi compounds, and enhanced precision in gene targeting. Its integration with other genomic tools like CRISPR enhances its utility in genomic research. Additionally, the rising demand for personalized medicine, where RNAi's specificity can tailor treatments to individual genetic profiles, highlights its potential in custom therapeutic strategies. In agriculture, RNAi's application in developing crops with increased yield, pest resistance, and improved nutritional profiles demonstrates its contribution to sustainable practices. Regulatory approvals for RNAi-based therapeutics and substantial funding from both public and private sectors are accelerating the adoption and development of RNAi technologies, promising significant advancements in gene therapy, drug development, and environmental sustainability.

Select Competitors (Total 12 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Benitec BioPharma
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Qiagen, Inc.
  • Quark Pharmaceuticals, Inc.
  • Silence Therapeutics PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • RNA Interference (RNAi) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in RNAi Delivery Technologies Expand Addressable Market Opportunity
    • Increasing Investment in RNAi Research and Development Propels Growth
    • Successful Clinical Trials Throws the Spotlight on RNAi Therapeutics
    • Rising Prevalence of Chronic Diseases Drives Adoption of RNAi Solutions
    • Innovations in Nanoparticle Delivery Systems Spur Market Adoption
    • Integration with CRISPR and Gene Editing Technologies Generates Demand
    • Expanding Applications in Oncology and Rare Diseases Sustain Growth
    • Advancements in Bioinformatics and Computational Biology Drive RNAi Research
    • Emergence of RNAi-based Therapeutics for Infectious Diseases Expands Market Opportunities
    • Rising Focus on Personalized Medicine Propels Growth in RNAi Applications
    • Challenges in Off-Target Effects and Safety Impact Adoption
    • Technological Innovations in siRNA and shRNA Constructs Drive Market Adoption
    • Integration with Drug Delivery Platforms Strengthens RNAi Efficacy
    • Cost Reductions in RNA Synthesis and Manufacturing Spur Market Growth
    • Technological Convergence with Other Therapeutic Modalities Expands Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Ocular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Ocular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Ocular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Respiratory Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Neuronal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Neuronal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Neuronal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World RNA Interference (RNAi) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • JAPAN
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • CHINA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • EUROPE
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • FRANCE
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • GERMANY
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • INDIA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030
  • AFRICA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제